The timing of antiparkinsonian treatment reduction after subthalamic nucleus stimulation

European Neurology

Volumn 49, Issue 1, 2003, Pages 59-63

  Thobois, Stephane ^a,d   Corvaisier, S ^b   Mertens, P ^c   Di Guardo, C ^b   Mollion, H ^a   Guenot, M ^c   Rochefort, F ^b   Chazot, G ^a   Sindou, M ^c   Broussolle, E ^a  

^a Hop Neurologique Pierre Wertheimer   (France)

^b Pharmaceutical Department   (France)

^c Neurosurgical Department A   (France)

^d Hop Neurologique Pierre Wertheimer   (France)

Author keywords

Antiparkinsonian treatment; Dopaminergic agonists; Levodopa; Parkinson's disease; Subthalamic nucleus stimulation

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BIPERIDEN; BROMOCRIPTINE; ENTACAPONE; LEVODOPA; LISURIDE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG COST; ELECTRODE; ELECTROSTIMULATION; FEMALE; FOLLOW UP; HUMAN; MALE; MONOTHERAPY; PARKINSON DISEASE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTRIC STIMULATION THERAPY; ELECTRODES, IMPLANTED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; POSTOPERATIVE CARE; SUBTHALAMIC NUCLEUS;

EID: 18744397818     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067028     Document Type: Article

References (15)

1. Pollak P, Benabid AL, Gross C, Gao DM, Laurent A, Benazzouz A, Hoffman D, Gentil M, Perret J: Effets de la stimulation du noyau sous-thalamique dans la maladie de Parkinson. Rev Neurol (Paris) 1993;149:175-176.
2. Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, Lang AE: Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 1998;51:850-855.
3. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL: Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339:1105-1111.
4. Moro E, Scerrati M, Romito LMA, Roselli R, Tonali P, Albanese A: Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 1999;53:85-90.
5. Pinter MM, Alesch F, Murg M, Seiwald M, Helscher RJ, Binder H: Deep brain stimulation of the subthalamic nucleus for control of extra-pyramidal features in advanced idiopathic Parkinson's disease: One year follow-up. J Neural Transm 1999;106:693-709.
6. Houeto JL, Damier P, Bejjani PB, Staedler C, Bonnet AM, Arnulf I, Pidoux B, Dormont D, Cornu P, Agid Y: Subthalamic stimulation in Parkinson's disease: A multidisciplinary approach. Arch Neurol 2000;57:461-465.
7. Molinuevo JL, Valldeoriola F, Tolosa E, Rumia J, Valls-Solé J, Roldan H, Ferrer E: Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson's disease. Arch Neurol 2000;57:983-988.
8. Lopiano L, Rizzone M, Bergamasco B, Tavella A, Torre E, Perozzo P, Valentini MC, Lanotte M: Deep brain stimulation of the subthalamic nucleus: Clinical effectiveness and safety. Neurology 2001;56:552-554.
9. Volkman J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V: Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001;56:548-551.
10. Thobois S, Mertens P, Guenot M, Hermier M, Mollion H, Bouvard M, Chazot G, Broussolle E, Sindou M: Subthalamic nucleus stimulation in Parkinson's disease: Clinical evaluation of 18 patients. J Neurol 2002;249:529-534.
11. Krack P, Fraix V, Mendes A, Benabid AL, Pollak P: Postoperative management of subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 2002;17(suppl 3):S188-S197.
12. Fraix V, Pollak P, Van Blercom N, Xie J, Krack P, Koudsie A, Benabid AL: Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. Neurology 2000;55:1921-1923.
13. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ: Hedonistic homeostatic dys-regulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.
14. Bejjani PB, Gervais D, Arnulf I, Papadopoulos S, Demeret S, Bonnet AM, Cornu P, Damier P, Agid Y: Axial parkinsonian symptoms can be improved: The role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry 2000;68:595-600.
15. Tomaszewski KJ, Holloway RG: Deep brain stimulation in the treatment of Parkinson's disease: A cost-effectiveness analysis. Neurology 2001;57:663-671.